Retinoblastoma Protein and CCAAT/Enhancer-Binding Protein β Are Required for 1,25-Dihydroxyvitamin D3-Induced Monocytic Differentiation of HL60 Cells

Cancer Research

Volumn 64, Issue 1, 2004, Pages 370-377

  Ji, Yan ^a   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,24 TRIHYDROXY 26,27 CYCLO 9,10 SECOCHOLESTA 5,7,10(19),22 TETRAENE 25 CARBOXYLIC ACID BUTYL ESTER; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTISENSE OLIGONUCLEOTIDE; CALCITRIOL; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CD14 ANTIGEN; ESTERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN INHIBITOR; RETINOBLASTOMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KINETICS; LEUKEMIA; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

CALCITRIOL; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL DIFFERENTIATION; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; KINETICS; MONOCYTES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 1642453788     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3029     Document Type: Article

References (67)

1. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Zhoa, L., Gu, L. J., and Wang, Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72: 567-572, 1988.
2. Castaigne, S., Chomienne, C., Daniel, M. T., Berger, R., Miclea, J. M., Ballerini, P., and Degos, L. Retinoic acids in the treatment of acute promyelocytic leukemia. Nouv. Rev. Fr. Hematol., 32: 36-38, 1990.
3. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med., 324: 1385-1393, 1991.
4. Sporn, M. B. New agents for chemoprevention of prostate cancer. Eur. Urol., 35: 420-423, 1999.
5. Gulliford, T., English, J., Colston, K. W., Menday, P., Moller, S., and Coombes, R. C. A Phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer, 78: 6-13, 1998.
6. Dalhoff, K., Dancey, J., Astrup, L., Skovsgaard, T., Hamberg, K. J., Lofts, F. J., Rosmorduc, c., Erlinger, S., Bach Hansen, J., Steward, W. P., Skov, T., Burcharth, F., and Evans, T. R. A Phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer, 89: 252-257, 2003.
7. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
8. Lee, W. H., Bookstein, R., Hong, F., Young, L. J., Shew, J. Y., and Lee, E. Y. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science (Wash. DC), 235: 1394-1399, 1987.
9. Classon, M., and Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer, 2: 910-917. 2002.
10. Stiegler, P., Kasten, M., and Giordano, A. The RB family of cell cycle regulatory factors. J. Cell. Biochem. Suppl., 30-31: 30-36, 1998.
11. Juan, G., Li, X., and Darzynkiewicz, Z. Phosphorylation of retinoblastoma protein assayed in individual HL-60 cells during their proliferation and differentiation. Exp. Cell Res., 244: 83-92, 1998.
12. Chen, P. L., Scully, P., Shew, J. Y., Wang, J. Y., and Lee, W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198, 1989.
13. Stirdivant, S. M., Ahern, J. D., Oliff, A., and Heimbrook, D. C. Retinoblastoma protein binding properties are dependent on 4 cysteine residues in the protein binding pocket. J. Biol. Chem., 267: 14846-14851, 1992.
14. Ewen, M. E., Faha, B., Harlow, E., and Livingston, D. M. Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science (Wash. DC), 255: 85-87, 1992.
15. Nevins, J. R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ., 9: 585-593, 1998.
16. Blagosklonny, M. V., and Pardee, A. B. The restriction point of the cell cycle. Cell Cycle, 1: 103-110, 2002.
17. 1/S-regulatory genes. Mol. Cell. Biol., 15: 4215-4224, 1995.
18. Puri, P. L., Iezzi, S., Stiegler, P., Chen, T. T., Schiltz, R. L., Muscat, G. E., Giordano, A., Kedes, L., Wang, J. Y., and Sartorelli, V. Class 1 histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis. Mol. Cell, 8: 885-897, 2001.
19. Lemercier, C., Duncliffe, K., Boibessot, I., Zhang, H., Verdel, A., Angelov, D., and Khochbin, S. Involvement of retinoblastoma protein and HBP1 in histone H1(0) gene expression. Mol. Cell. Biol., 20: 6627-6637, 2000.
20. Shih, H. H., Tevosian, S. G., and Yee, A. S. Regulation of differentiation by HBP1, a target of the retinoblastoma protein. Mol. Cell. Biol., 18: 4732-4743, 1998.
21. Radomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., and Tenen, D. G. CCAAT/enhancer binding protein α is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol., 18: 4301-4314, 1998.
22. Chen, P. L., Riley, D. J., Chen-Kiang, S., and Lee. W. H. Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. Proc. Natl. Acad. Sci. USA, 93: 465-469, 1996.
23. Szekely, L., Jin, P., Jiang, W. Q., Rosen, A., Wiman, K. G., Klein, G., and Ringertz, N. Position-dependent nuclear accumulation of the retinoblastoma (RB) protein during in vitro myogenesis. J. Cell. Physiol., 155: 313-322, 1993.
24. Cao, Z., Umek, R. M., and McKnight, S. L. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev., 5: 1538-1552, 1991.
25. Porse, B. T., Pedersen, T. A., Xu, X., Lindberg, B., Wewer, U. M., Friis-Hansen, L., and Nerlov, C. E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell, 107: 247-258, 2001.
26. Thomas, D. M., Carty, S. A., Piscopo, D. M., Lee, J. S., Wang, W. F., Forrester, W. C., and Hinds, P. W. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol. Cell, 8: 303-316, 2001.
27. Condorelli, G. L., Testa, U., Valtieri, M., Vitelli, L., De Luca, A., Barberi, T., Montesoro, E., Campisi, S., Giordano, A., and Peschle, C. Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation. Proc. Natl. Acad. Sci. USA, 92: 4808-4812, 1995.
28. Scott, L. M., Civin, C. I., Rorth, P., and Friedman, A. D. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood, 80: 1725-1735, 1992.
29. Lekstrom-Himes, J., and Xanthopoulos, K. G. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J. Biol. Chem., 273: 28545-28548, 1998.
30. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle, 1: 410-415, 2002.
31. 3. J. Cell. Biochem., 89: 1087-1101, 2003.
32. Wang, X., and Studzinski, G. P. Inhibition of p38MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J. Cell. Biochem., 82: 68-77, 2001.
33. 3-induced differentiation of HL60 cells. J. Cell. Biochem., 80: 471-482, 2001.
34. Gallagher, R., Collins, S., Trujillo, J., McCredie, K., Ahearn, M., Tsai, S., Metzgar, R., Aulakh, G., Ting, R., Ruscetti, F., and Gallo, R. Characterization of the continous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood, 54: 713-733, 1979.
35. 3 correlates with reduced rate of maturation of DNA replication intermerdiates. Cancer Res., 51: 3451-3455, 1991.
36. 3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated pathways. J. Cell. Physiol., 191: 198-207, 2002.
37. Bielinska, A., Shivdasani, R. A., Zhang, L. Q., and Nabel, G. J. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science (Wash. DC). 250: 997-1000, 1990.
38. Classon, M., Salama, S., Gorka, C., Mulloy, R., Braun, P., and Harlow. E. Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc. Natl. Acad. Sci. USA, 97: 10820-10825, 2000.
39. Vuocolo, S. C., Purev, E., Zhang, D., Bartek, J., Hansen, K., Soprano, D. R., and Soprano, K. J. Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid induced growth suppression of ovarian carcinoma cells. J. Biol. Chem., 278: 41881-41889, 2003.
40. 1 cell state. Mol. Cell. Biol., 16: 6965-6976, 1996.
41. Sidle, A., Palaty, C., Dirks, P., Wiggan, O., Kiess, M., Gill, R. M., Wong, A. K., and Hamel, P. A. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit. Rev. Biochem. Mol. Biol., 31: 237-271, 1996.
42. Christy, R. J., Yang, V. W., Ntambi, J. M., Geiman, D. E., Landschuiz, W. H., Friedman, A. D., Nakabeppu, Y., Kelly, T. J., and Lane, M. D. Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte specific genes. Genes Dev., 3: 1323-1335, 1989.
43. Agre, P., Johnson, P. F., and McKnight, S. L. Cognate DNA binding specificity retained after leucine zipper exchange between GCN4 and C/EBP. Science (Wash. DC), 246: 922-926. 1989.
44. Poli, V., Mancini, F. P., and Cortese, R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell, 63: 643-653, 1990.
45. Zhang, P., Nelson, E., Radomska, H. S., Iwasaki-Arai, J., Akashi, K., Friedman, A. D., and Tenen, D. G. Induction of granulocytic differentiation by two pathways. Blood, 99: 4406-4412, 2002.
46. Tanaka, T., Akira, S., Yoshida, K., Umemoto, M., Yoneda, Y., Shirafuji, N., Fujiwara, H., Suematsu, S., Yoshida, N., and Kishimoto, T. Targeted disruption of the NF-1L6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell, 80: 353-361, 1995.
47. Screpanti, I., Romani, L., Musiani, P., Modesti, A., Fattori, E., Lazzaro, D., Sellitio, C., Scarpa, S., Bellavia, D., Lattanzio. G., et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP β-deficient mice. EMBO J. 14: 1932-1941, 1995.
48. 3 show cell-specific actions. Chem. Biol., 7: 885-894, 2000.
49. Wang, X., and Studzinski, G. P. Phosphorylation of raf-1 by kinase suppressor of ras is inhibited by "MEK-specific" inhibitors PD 098059 and U0126 in differentiating HL60 cells. Exp. Cell Res., 268: 294-300, 2001.
50. 3 induced activation and subsequent nuclear translocation of MAPK is upstream regulated by PKC in HL-60 cells. Biochem. Biophys. Res. Commun., 241: 419-426, 1997.
51. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem., 270: 27489-27494, 1995.
52. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98: 13681-13686, 2001.
53. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 364: 229-233, 1995.
54. 1 to S phase block in polyploid HL60 cells. J. Cell. Physiol., 168: 18-25, 1996.
55. Studzinski, G. P., Rathod, B., Wang, Q. M., Rao, J., and Zhang, F. Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. Exp. Cell Res., 232: 376-387, 1997.
56. Brown, G., Choudhry, M. A., Durham, J., Drayson, M. T., and Michell, R. H. Monocytically differentiating HL60 cells proliferate rapidly before they mature. Exp. Cell Res., 253: 511-518, 1999.
57. 3 of all-trans-retinoic acid. Exp. Cell Res., 266: 126-134, 2001.
58. Studzinski, G. P., Bhandal, A. K., and Brelvi, Z. S. A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxychole-calciferol. Proc. Soc. Exp. Biol. Med., 179: 288-295, 1985.
59. 3-resistant HL60 cells is preceded by reduced growth factor dependence and constitutive up-regulation of Sp1 and AP-1 transcription factors. Cancer Res., 56: 5513-5521, 1996.
60. 3 in the murine myelomonocytic leukemia cell line WEHI-3. Cancer Res., 46: 6316-6321, 1986.
61. Yam, L. T., Li, C. Y., and Crosby, W. H. Cytochemical identification of monocytes and granulocytes. Am. J. Clin. Pathol., 55: 283-290, 1971.
62. 3 in HL60 cells. Cancer Res., 56: 264-267, 1996.
63. Meldrum, R. A., Bowl, M., Ong, S. B., and Richardson, S. Optimisation of electroporation for biochemical experiments in live cells. Biochem. Biophys. Res. Commun., 256: 235-239, 1999.
64. Melkonyan, H., Sorg, C., and Klempt, M. Electroporation efficiency in mammalian cells is increased by dimethyl sulfoxide (DMSO). Nucleic Acids Res., 24: 4356-4357, 1996.
65. Kusumawati, A., Commes, T., Liautard, J. P., and Widada, J. S. Transfection of myelomonocytic cell lines: cellular response to a lipid-based reagent and electroporation. Anal. Biochem., 269: 219-221, 1999.
66. Cobb, M. H., and Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 270: 14843-14846, 1995.
67. 3-induced growth inhibition. J. Biol. Chem., 277: 25884-25892, 2002.